A randomized, multicenter, open-label, blinded end point trial comparing the effects of spironolactone to chlorthalidone on left ventricular mass in patients with early-stage chronic kidney disease: Rationale and design of the SPIRO-CKD trial - Manvir K. Hayer, Nicola C. Edwards, Gemma Slinn, William E. Moody, Rick P. Steeds, Charles J. Ferro, Anna M. Price, Cecilio Andujar, Mary Dutton, Rachel Webster, David J. Webb, Scott Semple, Iain MacIntyre, Vanessa Melville, Ian B. Wilkinson - Dissemin

Language
Login

Published in

Elsevier, American Heart Journal, (191), p. 37-46

DOI: 10.1016/j.ahj.2017.05.008

Links

Elsevier | PDF

Tools

Export citation

Search in Google Scholar

A randomized, multicenter, open-label, blinded end point trial comparing the effects of spironolactone to chlorthalidone on left ventricular mass in patients with early-stage chronic kidney disease: Rationale and design of the SPIRO-CKD trial

Journal article published in 2017 by Manvir K. Hayer, Nicola C. Edwards, Gemma Slinn, William E. Moody, Rick P. Steeds, Charles J. Ferro, Anna M. Price, Cecilio Andujar, Mary Dutton, Rachel Webster, David J. Webb, Scott Semple, Iain MacIntyre, Vanessa Melville, Ian B. Wilkinson and other authors.

This paper is made freely available by the publisher.

This paper is made freely available by the publisher.

Full text: Download

Green circle

Preprint: archiving allowed

Upload

Orange circle

Postprint: archiving restricted

Upload

Red circle

Published version: archiving forbidden

Policy details

Data provided by

SHERPA/RoMEO